Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$74.85 ▲ +0.65
(+0.88%)
MKT CAP: $3.66B • VOL: 595.2K
52W L $54 52W H $92
TARS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $451.4M | $183.0M | $17.4M |
| YoY Revenue Growth % | +146.7% | +948.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$71.0M | -$120.6M | -$143.2M |
| Operating Margin % | -15.7% | -65.9% | -80.0% |
| Net Income (GAAP) | -$66.0M | -$116.0M | -$136.0M |
| EBITDA (Normalized) | -$63.1M | -$119.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$12.5M | -$83.0M | -$117.5M |
| Capital Expenditures (CapEx) | $9.9M | $1.6M | — |
| Free Cash Flow (FCF) | -$22.3M | -$84.6M | -$117.5M |
| FCF Margin % | -4.9% | -46.2% | -80.0% |
| Return on Invested Capital (ROIC %) | -24.1% | -45.0% | — |
| Cash & Short-Term Equivalents | $183.6M | $94.8M | — |
| Total Debt (Short + Long Term) | $72.4M | $71.8M | — |
| Total Stockholders' Equity | $343.4M | $224.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TARS.